Cite
HARVARD Citation
Choi, W. et al. (2020). Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma. Hepatology communications. 4 (7), pp. 1073-1086. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Choi, W. et al. (2020). Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma. Hepatology communications. 4 (7), pp. 1073-1086. [Online].